Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market

Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.